Dubai, UAE - The Emirates Drug Authority (EDA) signed a memorandum of understanding with Novo Nordisk, a global leader in developing treatments for diabetes, obesity and rare diseases, with the aim of strengthening cooperation in the field of pharmaceutical manufacturing using the latest technologies, and promoting an advanced and sustainable pharmaceutical system that supports innovation .

The memorandum focuses on raising the level of cooperation in the areas of supply chain security by increasing local added value and expanding partnerships that support the continuity of pharmaceutical supplies, which contributes to enhancing the resilience of the health sector and the sustainability of the availability of pharmaceutical products .

The agreement also includes capacity-building and national competency development programs through training initiatives, knowledge exchange, and professional qualification pathways, in addition to involving national cadres and students in academic and applied programs within the pharmaceutical work environment .

In the area of innovation, research and development, the memorandum includes creating a supportive regulatory environment to accelerate the introduction of modern treatments and expand access to them, in addition to enhancing the participation of institutions and relevant bodies in the UAE in product development projects and research related to the company’s activities .

This partnership contributes to enabling the readiness of the pharmaceutical sector in the UAE, consolidating the sustainability of its system, expanding the horizons of innovation and development, and supporting the country’s position among the most prominent regional and international centers in advanced pharmaceutical industries .

-I finish-

#Company Data

Disclaimer regarding the content of press releases
The content of this press release is provided by a third-party provider. We do not assume any responsibility for, nor do we have any control over, such content. This content is provided on an "as is" and "as available" basis and is not edited in any way. Neither we, nor our affiliates, will be liable for the accuracy, endorsement, or completeness of any opinions, views, information, or materials contained in this content.
This press release is provided for informational purposes only; the content does not constitute legal, investment, or tax advice, nor does it offer any opinion on the suitability, value, or profitability of any particular portfolio or investment strategy. Neither we nor our affiliates will be liable for any errors or inaccuracies in the content, or for any actions you take based on that content. You expressly agree and acknowledge full responsibility for your use of the information contained in this press release.
To the extent permitted by applicable law, Refinitiv, its parent company, subsidiaries, affiliates, relevant shareholders, directors, officers, employees, agents, advertisers, content providers, and licensors (collectively, the 'Refinitiv Parties') shall not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive, or exemplary damages; This includes, but is not limited to, losses of profits, savings, or revenues, whether due to negligence, tort, contract, or other theories of liability, even if the parties to Refinitiv were advised of the possibility of any such damages or losses occurring or actually anticipated them.